$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Whether Elacetrant has been included in the medical insurance catalog and interpretation of relevant policies on medical insurance reimbursement
2026-02-01 22:25:32
Check Details
What is the therapeutic effect of F/TAF and a summary of clinical research and patient medication feedback?
2026-02-01 22:25:32
Check Details
Analysis of whether long-term use of Febuxostat (Febuxostat) is necessary once you start taking it
2026-02-01 22:25:32
Check Details
Analysis of the main functions, efficacy and clinical indications of furmonertinib
2026-02-01 22:25:32
Check Details
Analysis of whether long-term persistence is required after taking ensifentrine-Ohtuvayre and the risk of discontinuation
2026-02-01 22:25:32
Check Details
Discussion on whether Roaccutane (isotretinoin) is a hormonal drug and its long-term safety
2026-02-01 22:25:32
Check Details
Detailed instructions for standard usage, dosage and injection method of Doxorubicin
2026-02-01 22:25:32
Check Details
Common side effects of everolimus (Afinitor) and precautions for safe use
2026-02-01 22:25:32
Check Details
Summary of usage standards and medication precautions for estramustine (Adelox)
2026-02-01 22:25:32
Check Details
Changes in patients’ financial burden after Pralsetinib is covered by medical insurance
2026-02-01 22:25:32
Check Details
Capmatinib dose adjustment recommendations for patients with renal impairment
2026-02-01 22:25:32
Check Details
List of contraindications for which drugs Sotolaxib (AMG 510) should not be taken at the same time
2026-02-01 22:25:32
Check Details
1
2
...
2148
2149
2150
2151
2152
2153
2154
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Brensoctib: Managing Side Effects of the Novel DPP-1 Inhibitor for Bronchiectasis
2
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
3
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
4
Trelagliptin: The First Once-Weekly DPP-4 Inhibitor Revolutionizing Type 2 Diabetes Care
5
Adagrasib Medication Management Guide for Special Populations
6
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
7
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
8
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
9
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
10
Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment
11
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
12
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma